Relevant gene combination, primer, probe and application used for detecting chemotherapeutic effect on acute myelogenous leukemia

Abstract

The invention discloses a relevant gene combination, a primer, a probe and application used for detecting a chemotherapeutic effect on acute myelogenous leukemia. The gene combination comprises four gene combinations closely relevant to pharmacotherapy of the acute myelogenous leukemia: medicament metabolism phase I enzyme gene CYP3A5, medicament metabolism phase II enzyme genes NAT2 and GSTO2, and medicament transport protein gene OATP1B1; and the gene combination comprises the following SNP loci: the locus rs776746 of the gene CYP3A5, the locus rs1799931 of the gene NAT2, the locus rs156697 of the gene GSTO2, and the locus rs4149056 of the gene OATP1B1. A method is performed by hybridizing a specific primer and probes which are subjected to fluorescence marks of different colors with target gene fragments in a nucleic acid sample after PCR amplification. The treatment effect of a leukemia medicament is detected and analyzed by mononucleotide extension technology so as to direct clinical medicament application, reduce a toxic or side effect of the medicament application for a patient, and increase a curative effect.

Description

technical field [0001] The present invention relates to a gene combination, primer, probe and application, especially a gene combination, primer, probe and application for detecting the curative effect of acute myeloid leukemia chemotherapy. Background technique [0002] Acute myeloid leukemia (AML) is a heterogeneous disease in which the normal differentiation of hematopoietic stem cells is blocked, and the clonal proliferation of malignant tumor cells replaces normal hematopoiesis, resulting in a series of symptoms such as anemia, hemorrhage, infection, and organ infiltration. Without treatment, patients die within weeks or months from bleeding or infection. The incidence of leukemia in my country is about 3-4 / 100,000. Among the death rates caused by malignant tumors, leukemia ranks first among children and adults under the age of 35, and is a killer that threatens the health of children and young and middle-aged people. In recent years, the incidence of acute myeloid le...

AI Technical Summary

Problems solved by technology

Changes in polymorphic sites of such enzymes will lead to differences in drug toxicity

Some experimental studies have shown that the NULL gene variants of GSTT1 and GSTM1 are not only related to the pathogenesis of acute leukemia, but also affect the therapeutic effect of chemotherapy and radiotherapy